Antiplatelet Aggregation and Platelet Activating Factor (PAF) Receptor Antagonistic Activities of the Essential Oils of Five Goniothalamus Species

Moharam, Bushra Abdulkarim; Jantan, Ibrahim; Ahmad, Fasihuddin B.; Jalil, Juriyati

doi:10.3390/molecules15085124

Cited by 19 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also inhibition (50 %) of AA-induced platelet aggregation (with an IC 50 of 93.6 μg/ml). Aspirin, which was used as the positive control in the study, was found to be a more potent cyclooxygenase inhibitor, since its IC 50 was much lower (4.5 μg/ml or 24.8 μM) than those of the oils investigated [42]. Furthermore, it is suggested that the antiplatelet activity of the Goniothalamus oils may not be due solely to any individual component but could be due to the synergistic effect of a combination of its compounds.…”

Section: +mentioning

confidence: 96%

“…Different parts of these plants are used in traditional medicine to treat conditions such as asthma, rheumatism, fever, malaria, cholera and stomach aches. The in vitro inhibitory effect of various oils from Goniothalamus species was observed for the first time, by Moharam et al [42]. The bark oil, identified as Gonystylus velutinus (100 μg/ml, distilled from Goniothalamus ) showed strong inhibition (51 %) of human platelet aggregation in whole blood, induced by ADP (10 μM, with an IC 50 of 87.7 μg/ml).…”

Section: +mentioning

confidence: 96%

“…Undoubtedly, it is also of interest to determine if brazilin does indeed affect the P 2 purinergic receptors in human platelets, as it can prospectively lead to the development of new 'natural' ADP receptor antagonists. Mitrephora plants (of the Annonaceae family), located in Borneo, Philippines, north China, the west of India, and the south-east of Australia, have been investigated for their chemical components [41,42]. In an exciting study, Moharam et al [41] examined the biological activity of the methanol extract of the twigs of Muraltia vulpina.…”

Section: +mentioning

confidence: 99%

“…The exact mechanism of the action of phylligenin is still unclear, although it has similar effects to aspirin, i.e. it inhibits thromboxane A 2 formation [41,42]. Furthermore, aspirin, a potent cyclooxygenase inhibitor, was used as a positive control for phylligenin and demonstrated a lower IC 50 (24.8 μM) [41].…”

Section: +mentioning

confidence: 99%

“…Additional evidence of antiplatelet activity via the ADP purinergic receptors with 'plant-derived' extracts can be seen with essential oils of five Goniothalamus species found in tropical Southeast Asia, throughout Indochina and Malaysia [42]. Different parts of these plants are used in traditional medicine to treat conditions such as asthma, rheumatism, fever, malaria, cholera and stomach aches.…”

Section: +mentioning

confidence: 99%

See 4 more Smart Citations

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Jagroop

2013

Purinergic Signalling

View full text Add to dashboard Cite

Adenosine diphosphate (ADP) plays a pivotal role in platelet activation. Platelet hyperactivity is associated with vascular disease and also has a key role in haemostasis and thrombosis. ADP activates platelets through three purinoceptor subtypes, the G q -coupled P2Y 1 receptor, G icoupled P2Y 12 receptor and P2X 1 ligand-gated cation channel. Platelet ADP purinergic receptors are therefore suitable targets for antiplatelet drugs. Thienopyridines such as clopidogrel and ticlopidine, as well as other ADP receptor antagonists like prasugrel, ticagrelor, cangrelor and elinogrel have demonstrated clinical benefits via the inhibition of the selective purinergic ADP receptor, P2Y 12 . However, they still have limitations in their mode of action and efficacy, like increased risk of bleeding. Thus, the ongoing pursuit to develop newer and more effective antiplatelet agents continues. There is a growing interest in the purinergic antiplatelet properties exhibited by plant extracts. This article considers the following: pomolic acid isolated from Licania pittieri, brazilin isolated from the heartwood of Caesalpinia sappan L, phylligenin isolated from the twigs of Muraltia vulpina , bark oil of Gonystylus velutinus , seed and bark extracts from Aesculus hippocastanum L . and red wine phenolics and catechins isolated from green tea. Moreover, the method used to investigate platelet purinergic receptors should be considered, since using a more sensitive, highresolution platelet sizer can sometimes detect platelet variations when the light transmission method was not able to do so. The exact mechanisms by which these plant extracts work need further investigation. They all however inhibit ADP-induced activation in human platelets. This could explain, at least in part, the protective effect of plant extracts as antiplatelet agents.

show abstract

Section: +mentioning

confidence: 96%

Section: +mentioning

confidence: 96%

Section: +mentioning

confidence: 99%

Section: +mentioning

confidence: 99%

Section: +mentioning

confidence: 99%

See 3 more Smart Citations

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Jagroop

2013

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID‐19

Mukherjee

Chattopadhyay

2022

Phytotherapy Research

View full text Add to dashboard Cite

Thrombotic complications occur in many cardiovascular pathologies and have been demonstrated in COVID‐19. The currently used antithrombotic drugs are not free of adverse reactions, and COVID‐19 patients in particular, when treated with a therapeutic dose of an anticoagulant do not receive mortality benefits. The clinical management of COVID‐19 is one of the most difficult tasks for clinicians, and the search for safe, potent, and effective antithrombotic drugs may benefit from exploring naturally bioactive molecules from plant sources. This review describes recent advances in understanding the antithrombotic potential of herbal drug prototypes and points to their future clinical use as potent antithrombotic drugs. Although natural products are perceived to be safe, their clinical and therapeutic applications are not always apparent or accepted. More in‐depth studies are necessary to demonstrate the clinical usefulness of plant‐derived, bioactive compounds. In addition, holistic approaches in systematic investigations and the identification of antithrombotic mechanisms of the herbal bioactive molecule(s) need to be conducted in pre‐clinical studies. Moreover, rigorous studies are needed to compare the potency of herbal drugs to that of competitor chemical antithrombotic drugs, and to examine their interactions with Western antithrombotic medicines. We have also proposed a road map to improve the commercialization of phytopharmaceuticals.

show abstract

Essential Oil Toxicity and Contraindications

Buckle¹

2015

Clinical Aromatherapy

View full text Add to dashboard Cite

Antiplatelet Aggregation and Platelet Activating Factor (PAF) Receptor Antagonistic Activities of the Essential Oils of Five Goniothalamus Species

Cited by 19 publications

References 21 publications

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID‐19

Essential Oil Toxicity and Contraindications

Contact Info

Product

Resources

About